Free Trial

Wall Street Zen Upgrades PROCEPT BioRobotics (NASDAQ:PRCT) to Hold

PROCEPT BioRobotics logo with Medical background

Wall Street Zen upgraded shares of PROCEPT BioRobotics (NASDAQ:PRCT - Free Report) from a sell rating to a hold rating in a research note published on Saturday morning.

A number of other research firms have also recently weighed in on PRCT. Bank of America dropped their target price on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating on the stock in a research note on Friday, April 25th. Truist Financial decreased their price target on PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating on the stock in a research note on Friday, April 11th. Finally, Morgan Stanley reduced their target price on PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $90.00.

Read Our Latest Analysis on PROCEPT BioRobotics

PROCEPT BioRobotics Price Performance

PROCEPT BioRobotics stock traded down $0.28 during mid-day trading on Friday, reaching $58.36. The company had a trading volume of 103,707 shares, compared to its average volume of 816,814. The business has a fifty day simple moving average of $55.29 and a 200 day simple moving average of $70.00. The company has a market cap of $3.23 billion, a P/E ratio of -29.83 and a beta of 1.10. PROCEPT BioRobotics has a fifty-two week low of $47.04 and a fifty-two week high of $103.81. The company has a current ratio of 6.02, a quick ratio of 5.07 and a debt-to-equity ratio of 0.21.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The company reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.04. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The firm had revenue of $69.16 million during the quarter, compared to the consensus estimate of $65.39 million. During the same period last year, the business posted ($0.51) EPS. The business's revenue was up 55.5% compared to the same quarter last year. On average, equities research analysts predict that PROCEPT BioRobotics will post -1.75 earnings per share for the current year.

Insider Activity at PROCEPT BioRobotics

In other news, CEO Reza Zadno sold 5,475 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $312,403.50. Following the transaction, the chief executive officer now owns 173,070 shares of the company's stock, valued at approximately $9,875,374.20. The trade was a 3.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Kevin Waters sold 733 shares of the stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $41,824.98. Following the completion of the sale, the chief financial officer now owns 107,991 shares in the company, valued at approximately $6,161,966.46. The trade was a 0.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 6,455 shares of company stock worth $368,322. 6.60% of the stock is owned by company insiders.

Institutional Trading of PROCEPT BioRobotics

A number of institutional investors have recently made changes to their positions in the business. ANTIPODES PARTNERS Ltd purchased a new position in shares of PROCEPT BioRobotics during the 1st quarter valued at approximately $30,000. Raleigh Capital Management Inc. purchased a new position in shares of PROCEPT BioRobotics during the fourth quarter worth $32,000. BI Asset Management Fondsmaeglerselskab A S purchased a new position in PROCEPT BioRobotics in the 1st quarter valued at approximately $40,000. Thematics Asset Management purchased a new stake in PROCEPT BioRobotics during the 4th quarter worth about $46,000. Finally, CWM LLC increased its position in shares of PROCEPT BioRobotics by 69.5% in the 1st quarter. CWM LLC now owns 873 shares of the company's stock valued at $51,000 after purchasing an additional 358 shares during the last quarter. Institutional investors and hedge funds own 89.46% of the company's stock.

About PROCEPT BioRobotics

(Get Free Report)

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).

Featured Articles

Analyst Recommendations for PROCEPT BioRobotics (NASDAQ:PRCT)

Should You Invest $1,000 in PROCEPT BioRobotics Right Now?

Before you consider PROCEPT BioRobotics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PROCEPT BioRobotics wasn't on the list.

While PROCEPT BioRobotics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines